Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy

Amy K. Clippinger, Simon D'Alton, Wen Lang Lin, Tania F. Gendron, John Howard, David R. Borchelt, Ashley Cannon, Yari Carlomagno, Paramita Chakrabarty, Casey Cook, Todd E. Golde, Yona Levites, Laura Ranum, Patrick J. Schultheis, Guilian Xu, Leonard Petrucelli, Naruhiko Sahara, Dennis W. Dickson, Benoit Giasson, Jada Lewis

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Frontotemporal lobar degeneration (FTLD) has been subdivided based on the main pathology found in the brains of affected individuals. When the primary pathology is aggregated, hyperphosphorylated tau, the pathological diagnosis is FTLD-tau. When the primary pathology is cytoplasmic and/or nuclear aggregates of phosphorylated TAR-DNA-binding protein (TDP-43), the pathological diagnosis is FTLD-TDP. Notably, TDP-43 pathology can also occur in conjunction with a number of neurodegenerative disorders; however, unknown environmental and genetic factors may regulate this TDP-43 pathology. Using transgenic mouse models of several diseases of the central nervous system, we explored whether a primary proteinopathy might secondarily drive TDP-43 proteinopathy. We found abnormal, cytoplasmic accumulation of phosphorylated TDP-43 specifically in two tau transgenic models, but TDP-43 pathology was absent in mouse models of Aβ deposition, α-synucleinopathy or Huntington's disease. Though tau pathology showed considerable overlap with cytoplasmic, phosphorylated TDP-43, tau pathology generally preceded TDP-43 pathology. Biochemical analysis confirmed the presence of TDP-43 abnormalities in the tau mice, which showed increased levels of high molecular weight, soluble TDP-43 and insoluble full-length and ~35 kD TDP-43. These data demonstrate that the neurodegenerative cascade associated with a primary tauopathy in tau transgenic mice can also promote TDP-43 abnormalities. These findings provide the first in vivo models to understand how TDP-43 pathology may arise as a secondary consequence of a primary proteinopathy.

Original languageEnglish (US)
Pages (from-to)39-50
Number of pages12
JournalActa neuropathologica
Volume126
Issue number1
DOIs
StatePublished - Jul 1 2013

Keywords

  • Mouse
  • Neuropathology, tauopathy
  • TDP-43
  • TDP-43 proteinopathies
  • Tau
  • Transgenic

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy'. Together they form a unique fingerprint.

  • Cite this

    Clippinger, A. K., D'Alton, S., Lin, W. L., Gendron, T. F., Howard, J., Borchelt, D. R., Cannon, A., Carlomagno, Y., Chakrabarty, P., Cook, C., Golde, T. E., Levites, Y., Ranum, L., Schultheis, P. J., Xu, G., Petrucelli, L., Sahara, N., Dickson, D. W., Giasson, B., & Lewis, J. (2013). Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. Acta neuropathologica, 126(1), 39-50. https://doi.org/10.1007/s00401-013-1123-8